natgillin/translations-raw huggingface dataset:
Severe hypoglycaemia may lead to unconsciousness and/ or convulsions and may result in temporary or permanent impairment of brain function or even death.
Huda hipoglikemija lahko povzro i nezavest in/ ali konvulzije in ima za posledico lahko prehodno ali trajno okvaro delovanja možganov ali celo smrt.
In clinical trials and during marketed use the frequency varies with patient population and dose regimens therefore no specific frequency can be presented.
Pogostnost v klini nih preskušanjih in med uporabo, ko je insulin že na trgu, se spreminja glede na populacijo bolnikov in odmerne sheme, zato natan ne pogostnosti ni mogo e navesti.
During clinical trials the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.
V klini nih preskušanjih ni bilo razlik med celotnim deležem hipoglikemij pri bolnikih, zdravljenih z insulinom aspart, in bolnikih, ki so dobivali humani insulin.
Frequencies of adverse drug reactions from clinical trials, which by an overall judgement are considered related to insulin aspart are listed below.
Spodaj so navedene pogostnosti neželenih reakcij, ki so bile zabeležene v klini nih preskušanjih in po splošni presoji veljajo za povezane z insulinom aspart.
Uncommon (> 1/ 1,000 ,< 1/100) and rare (> 1/10 ,000, < 1/1,000).
Pogostnosti so opredeljene kot: ob asno (> 1/ 1. 000, < 1/ 100) in redko (> 1/ 10. 000, < 1/ 1. 000).
Isolated spontaneous cases are presented as very rare defined as (< 1/ 10,000), including isolated reports.
Posamezni spontani primeri so opisani kot zelo redki in opredeljeni kot (< 1/ 10. 000), vklju no s posameznimi primeri.
Immune system disorders Uncommon - Urticaria, rash, eruptions
Bolezni imunskega sistema Ob asno - urtikarija, izpuš aj, erupcije
Very rare - Anaphylactic reactions Symptoms of generalised hypersensitivity may include generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure.
Zelo redko - anafilakti ne reakcije Med simptomi generalizirane preob utljivosti so lahko generaliziran izpuš aj na koži, srbenje,
Generalised hypersensitivity reactions are potentially life threatening.
Generalizirane preob utljivostne reakcije so lahko smrtno nevarne.
5 Nervous system disorders Rare - Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed acute painful neuropathy, which is usually reversible.
Bolezni živ evja Redko - periferna nevropatija Hitro izboljšanje urejenosti glukoze v krvi lahko spremlja motnja, imenovana akutna bole a nevropatija, ki je ponavadi reverzibilna.
Eye disorders Uncommon - Refraction disorder Refraction anomalies may occur upon initiation of insulin therapy.
O esne bolezni Ob asno - refrakcijske motnje Po za etku zdravljenja z insulinom se lahko pojavijo refrakcijske anomalije.
Uncommon - Diabetic retinopathy Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Ob asno - diabeti na retinopatija Dolgoro no izboljšana urejenost glikemije zmanjša tveganje za napredovanje diabeti ne retinopatije.
However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with worsening of diabetic retinopathy.
Vendar lahko intenziviranje insulinskega zdravljenja s hitrim izboljšanjem urejenosti glikemije spremlja poslabšanje diabeti ne retinopatije.
Skin and subcutaneous tissue disorders Uncommon - Lipodystrophy Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.
Bolezni kože in podkožja Ob asno - lipodistrofija e bolnik mest injiciranj na posameznem predelu ne menja krožno, se lahko pojavi lipodistrofija.
Uncommon - Local hypersensitivity Local hypersensitivity reactions (redness, swelling and itching at the injection site) may occur during treatment with insulin.
Ob asno - lokalna preob utljivost Med zdravljenjem z insulinom se lahko pojavijo lokalne preob utljivostne reakcije (pordelost, oteklina in srbenje na mestu injiciranja).
General disorders and administration site conditions Uncommon - Oedema Oedema may occur upon initiation of insulin therapy.
Splošne težave in spremembe na mestu aplikacije Redko - edemi Po za etku zdravljenja z insulinom se lahko pojavijo edemi.
Oedema and weight increase may occur when NovoMix 30 is used in combination with OADs.
Ti simptomi so ponavadi prehodni. e je zdravilo NovoMix 30 uporabljeno v kombinaciji s peroralnimi antidiabetiki, se lahko pojavijo edemi in pove anje telesne mase.
A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient’ s requirement are administered:
Specifi nega prevelikega odmerjanja insulina ni mogo e opredeliti, a e so uporabljeni odmerki preveliki glede na bolnikove potrebe, se lahko v zaporednih stopnjah razvije hipoglikemija:
It is therefore recommended that the diabetic patient always carry sugar-containing products • Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person or glucose given intravenously by a medical professional.
Zato naj ima sladkorni bolnik vedno pri sebi nekaj živil, ki vsebujejo sladkor. • Hude hipoglikemije, ko je bolnik nezavesten, je mogo e zdraviti z glukagonom (0, 5 do 1 mg), ki ga intramuskularno ali subkutano aplicira ustrezno podu ena oseba, ali z glukozo, ki jo intravensko aplicira zdravstveni delavec.
Glucose must also be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes.
Glukozo je treba aplicirati intravensko tudi v primeru, da se bolnik v 10 do 15 minutah ne odzove na glukagon.
Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.
Ko se bolnik zave, je priporo ljivo, da peroralno dobi ogljikove hidrate za prepre itev ponovitve.
Insulins and analogues for injection, intermediate-acting combined with fast-acting.
Insulini in analogi za injiciranje, s srednjedolgim delovanjem, s takojšnjim u inkom.
NovoMix 30 is a biphasic suspension of insulin aspart (rapid-acting human insulin analogue) and protamine-crystallised insulin aspart (intermediate-acting human insulin analogue).
Zdravilo NovoMix 30 je dvofazna suspenzija insulina aspart (hitrodelujo ega analoga humanega insulina) in s protaminom kristaliziranega insulina aspart (srednjedolgodelujo ega analoga humanega
6 The blood glucose lowering effect of insulin occurs when the molecules facilitate the uptake of glucose by binding to insulin receptors on muscle and fat cells - and simultaneously inhibit the output of glucose from the liver.
6 insulina).
NovoMix 30 is a biphasic insulin, which contains 30% soluble insulin aspart.
Zdravilo NovoMix 30 je dvofazen insulin, ki vsebuje 30% topnega insulina aspart.
This has a rapid onset of action, thus allowing it to be given closer to a meal (within zero to 10 minutes of the meal) when compared to soluble human insulin.
Ta za ne delovati hitro in tako omogo a uporabo bližje obroku (od ni do 10 minut od obroka) kot topni humani insulin.
The crystalline phase (70%) consists of protamine-crystallised insulin aspart, which has an activity profile that is similar to that of human NPH insulin (Figure 1).
Kristalno fazo (70%) sestavlja s protaminom kristalizirani insulin aspart, ki ima podoben potek delovanja kot humani insulin NPH (slika 1).
When NovoMix 30 is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection.
e se zdravilo NovoMix 30 injicira subkutano, za ne delovati v 10 do 20 minutah.
The maximum effect is exerted between 1 and 4 hours after injection.
Najve ji u inek doseže od 1 do 4 ure po injekciji.
The duration of action is up to 24 hours.
Trajanje delovanja je do 24 ur.
Activity profile of NovoMix 30 (___) and biphasic human insulin 30 (---) in healthy subjects.
Potek delovanja zdravila NovoMix 30 (___) in dvofaznega humanega insulina 30 (---) pri zdravih preiskovancih.
In a 3 month trial in patients with type 1 and type 2 diabetes NovoMix 30 showed equal control of glycosylated haemoglobin compared to treatment with biphasic human insulin 30.
V 3- mese nem preskušanju bolnikov z diabetesom tipa 1 in tipa 2 je bila urejenost glikiranega hemoglobina z zdravilom NovoMix 30 enaka kot med zdravljenjem z dvofaznim humanim insulinom 30.
Compared to biphasic human insulin 30, administration of NovoMix 30 before breakfast and dinner resulted in lower postprandial blood glucose after both meals (breakfast and dinner).
Uporaba zdravila NovoMix 30 pred zajtrkom in ve erjo je v primerjavi z uporabo dvofaznega humanega insulina 30 povzro ila nižjo postprandialno glukozo v krvi po obeh obrokih (zajtrk, ve erja).
A meta-analysis including nine trials in patients with type 1 and type 2 diabetes showed that fasting blood glucose was higher in patients treated with NovoMix 30, than in patients treated with biphasic human insulin 30.
Metaanaliza, ki je zajela devet preskušanj pri bolnikih z diabetesom tipa 1 in tipa 2, je pokazala, da je bila glukoza v krvi na teš e višja pri bolnikih, ki so dobivali zdravilo NovoMix 30, kot pri bolnikih, ki so dobivali dvofazni humani insulin 30.
In one study, 341 patients with type 2 diabetes were randomised to treatment with NovoMix 30 either alone or in combination with metformin, or to metformin together with sulfonylurea.
V eni študiji je bilo 341 bolnikov z diabetesom tipa 2 randomiziranih v skupine zdravljene samo z zdravilom NovoMix 30 ali s kombinacijo zdravila NovoMix 30 in metformina ali pa s kombinacijo metformina in sulfonilse nine.
The primary efficacy variable - HbA1c after 16 weeks of treatment - did not differ between patients with NovoMix 30 combined with metformin and patients with metformin plus sulfonylurea.
Primarni parameter u inkovitosti HbA1c po 16 tednih zdravljenja se ni razlikoval pri bolnikih zdravljenih z zdravilom NovoMix 30 in metforminom v primerjavi z bolniki zdravljenimi z metforminom in sulfonilse nino.
In this trial 57% of the patients had baseline HbA1c above 9%; in these patients treatment with NovoMix 30 in combination with metformin resulted in significantly lower HbA1c than metformin in combination with sulfonylurea.
V tej raziskavi je imelo 57% bolnikov na za etku HbA1c nad 9%; ti bolniki so imeli po zdravljenju z zdravilom NovoMix 30 v kombinaciji z metforminom signifikantno nižji HbA1c kot pa po zdravljenju s kombinacijo metformina in sulfonilse nine.
In one study, patients with type 2 diabetes, insufficiently controlled on oral hypoglycaemic agents alone, were randomised to treatment with twice daily NovoMix 30 (117 patients) or once daily insulin glargine (116 patients).
Po 28 tednih zdravljenja v skladu s smernicami za
After 28 weeks treatment following the dosing guideline outlined in section 4.2, the mean reduction in HbA1c was 2.8% with NovoMix 30 (mean at baseline = 9.7%).
7 odmerjanje, opisanimi v poglavju 4. 2, je bilo povpre no znižanje HbA1c z zdravilom NovoMix 30 2, 8% (povpre na izhodiš na vrednost je bila 9, 7%).
With NovoMix 30, 66% and 42% of the patients reached HbA1c levels below 7% and 6.5%, respectively, and mean FPG was reduced by about 7 mmol/ L (from 14.0 mmol/ L at baseline to 7.1 mmol/ L).
Z zdravilom NovoMix 30 je vrednosti HbA1c pod 7% doseglo 66% bolnikov, vrednosti pod 6, 5% pa 42% bolnikov; povpre na koncentracija glukoze v plazmi na teš e se je znižala za približno 7 mmol/ l (s 14, 0 mmol/ l izhodiš no na 7, 1 mmol/ l).
7 In patients with type 2 diabetes a meta-analysis showed a reduced risk of overall nocturnal hypoglycaemic episodes and major hypoglycaemia with NovoMix 30 compared to biphasic human insulin 30.
Metaanaliza je pri bolnikih z diabetesom tipa 2 pokazala manjše tveganje vseh no nih hipoglikemij in hudih hipoglikemij med uporabo zdravila NovoMix 30 kot med uporabo dvofaznega humanega insulina 30.
The risk of overall daytime hypoglycaemic episodes was increased in patients treated with NovoMix 30
Tveganje vseh hipoglikemij ez dan je bilo ve je pri bolnikih, ki so dobivali zdravilo NovoMix 30.
A 16-week clinical trial comparing postprandial glycaemic control of meal- related NovoMix 30 with meal-related human insulin/ biphasic human insulin 30 and bedtime NPH insulin was performed in 167 subjects aged 10 to 18 years.
Pri 167 preiskovancih, starih od 10 do 18 let, so opravili 16- tedensko klini no preskušanje.
Mean HbA1c remained similar to baseline throughout the trial in both treatment groups, and there was no difference in hypoglycaemia rate with NovoMix 30 or biphasic human insulin 30.
V njem so primerjali urejenost postprandialne glikemije med uporabo NovoMix 30 ob obrokih in uporabo humanega insulina/ bifaznega humanega insulina 30 ob obrokih ter NPH insulina pred spanjem.
In a smaller (54 subjects) and younger (age range 6 to 12 years) population, treated in a double-blind, cross-over trial (12 weeks on each treatment) the rate of hypoglycaemic episodes and the postprandial glucose increase was significantly lower with NovoMix 30 compared to biphasic human insulin 30.
V manjši (54 preiskovancev) in mlajši (starostni razpon od 6 do 12 let) populaciji v dvojno slepem navzkrižnem preskušanju (12 tednov na vsaki terapiji) je bil delež hipoglikemij in postprandialnih porastov glukoze med uporabo NovoMix 30 statisti no zna ilno manjši kot med uporabo bifaznega humanega insulina 30.
Final HbA1c was significantly lower in the biphasic human insulin 30 treated group compared with NovoMix 30.
Kon ni HbA1c je bil zna ilno nižji v skupini z bifaznim humanim insulinom 30 kot v skupini z NovoMix 30.
In insulin aspart substitution of amino acid proline with aspartic acid at position B28 reduces the tendency to form hexamers in the soluble fraction of NovoMix 30, as compared with soluble human insulin.
Substitucija aminokisline prolina z asparaginsko kislino na položaju B28 v insulinu aspart zmanjša nagnjenost k tvorbi heksamerov v topni frakciji zdravila NovoMix 30 v primerjavi s topnim humanim insulinom.
The insulin aspart in the soluble phase of NovoMix 30 comprises 30% of the total insulin; this is absorbed more rapidly from the subcutaneous layer than the soluble insulin component of biphasic human insulin.
Insulin aspart v topni fazi zdravila NovoMix 30 obsega 30% celotnega insulina: ta se iz podkožja absorbira hitreje kot topna insulinska komponenta dvofaznega humanega insulina.
The remaining 70% is in crystalline form as protamine-crystallised insulin aspart; this has a prolonged absorption profile similar to human NPH insulin.
Preostalih 70% v kristalni obliki je s protaminom kristalizirani insulin aspart, ki ima podaljšan potek absorpcije, podoben humanemu insulinu NPH.
The time to maximum concentration is, on average, half of that for biphasic human insulin 30.
Najve ja koncentracija insulina v serumu je pri zdravilu NovoMix 30 v povpre ju za 50% ve ja kot pri dvofaznem humanem insulinu 30. as do najve je koncentracije je v povpre ju pol krajši kot pri dvofaznem humanem insulinu 30.
In healthy volunteers a mean maximum serum concentration of 140 ± 32 pmol/ l was reached about 60 minutes after a subcutaneous dose of 0.20 U/ kg body weight.
Pri zdravih prostovoljcih je bila najve ja koncentracija v serumu 140 ± 32 pmol/ l dosežena okrog 60 minut po subkutanem odmerku 0, 20 e. / kg telesne mase.
The mean half life (t½) of NovoMix 30, reflecting the absorption rate of the protamine bound fraction, was about 8-9 hours.
Povpre ni razpolovni as (t1/ 2) zdravila NovoMix 30, ki odraža hitrost absorpcije na protamin vezane frakcije, je bil okrog 8 do 9 ur.
Serum insulin levels returned to baseline 15-18 hours after a subcutaneous dose.
Koncentracija insulina v serumu se je vrnila na izhodiš no od 15 do 18 ur po subkutanem odmerku.
In type 2 diabetic patients, the maximum concentration was reached about 95 minutes after dosing, and concentrations well above zero for not less than 14 hours post-dosing were measured.
Pri diabetikih tipa 2 je bila najve ja koncentracija dosežena približno 95 minut po uporabi in koncentracije ob utno nad ni so bile izmerjene ne manj kot 14 ur po uporabi.
The pharmacokinetics of NovoMix 30 has not been investigated in children or adolescents.
Farmakokinetika insulina NovoMix 30 pri otrocih in mladostnikih ni raziskana.
However, the pharmacokinetic and pharmacodynamic properties of soluble insulin aspart have been investigated in children (6– 12 years) and adolescents (13– 17 years) with type 1 diabetes.
Vendar so farmakokineti ne in farmakodinami ne lastnosti topnega insulina aspart raziskali pri otrocih (od 6. do 12. leta) in mladostnikih (od 13. do 17. leta) z diabetesom tipa 1.
The pharmacokinetics of NovoMix 30 has not been investigated in elderly, or patients with impaired renal or liver function.
Farmakokinetika zdravila NovoMix 30 ni raziskana pri starejših osebah in bolnikih z okvarjenim delovanjem ledvic ali jeter.
Non-clinical data with insulin aspart reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction.
Neklini ni podatki o insulinu aspart na osnovi obi ajnih študij farmakološke varnosti, toksi nosti pri ponavljajo ih se odmerkih, genotoksi nosti in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za loveka.
In in vitro tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin.
V preskusih in vitro, vklju no z vezavo na receptorska mesta za insulin in IGF- 1 ter u inki na celi no
Glycerol Phenol Metacresol Zinc (as chloride) Sodium chloride Disodium phosphate dihydrate Protamine sulphate Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections
glicerol fenol metakrezol cink (kot klorid) natrijev klorid natrijev hidrogenfosfat dihidrat protaminijev sulfat natrijev hidroksid (za uravnavo pH) klorovodikova kislina (za uravnavo pH) voda za injekcije
The in-use shelf life is 4 weeks (not above 30°C).
Rok uporabnosti med uporabo je 4 tedne (pri temperaturi do 30 °C).
Store in a refrigerator (2°C – 8°C) away from the freezing compartment.
Shranjujte v hladilniku pri temperaturi med 2 °C in 8 °C, ne blizu zamrzovalnega razdelka!
NovoMix 30 Penfill cartridges in use or carried as a spare: can be kept at ambient temperature (below 30°C) for up to 4 weeks, but any remainder must then be discarded.
Injekcijski vložki NovoMix 30 Penfill, ki so v uporabi ali jih ima bolnik pri sebi za rezervo: do 4 tedne jih je mogo e hraniti pri sobni temperaturi (do 30 °C), toda ostanek je treba po tem asu zavre i.
Do not refrigerate.
Ne shranjujte v hladilniku!
Keep the cartridges in the outer carton in order to protect from light.
Injekcijske vložke shranjujte v zunanji ovojnini za zagotovitev zaš ite pred svetlobo!
After removing NovoMix 30 Penfill from the refrigerator it is recommended to allow NovoMix 30 Penfill to reach room temperature before resuspending the insulin as instructed for the first time use.
Potem ko zdravilo NovoMix 30 Penfill vzamete iz hladilnika, ga je priporo ljivo pustiti, da doseže sobno temperaturo, preden insulin resuspendirate, kot opisujejo navodila za prvo uporabo.
The cartridge contains a glass ball to facilitate resuspension.
Steklen vložek (steklo tipa 1) je na enem koncu zaprt z batom iz (brombutilne) gume brez lateksa in na drugi strani z zaporko iz (brombutilne/ poliizoprenske) gume brez lateksa V vložku je steklena kroglica, ki olajša resuspendiranje.
Each cartridge contains 3 ml suspension.
Vsak vložek vsebuje 3 ml suspenzije.
Cartons of 5 or 10 cartridges.
Škatla s 5 ali 10 vložki.
The cartridges are designed to be used with Novo Nordisk delivery systems (durable devices for repeated use) and NovoFine needles.
Injekcijski vložki so namenjeni za uporabo v sistemih za dajanje insulina Novo Nordisk (trajni
Detailed instruction accompanying the cartridge and delivery system must be followed.
Upoštevati je treba podrobno navodilo, priloženo injekcijskim vložkom in aplikacijskemu sisitemu
NovoMix 30 Penfill is for use by one person only.
Vložek NovoMix 30 Penfill je namenjen uporabi ene same osebe.
9 The necessity of resuspending the NovoMix 30 suspension immediately before use is to be stressed to the patient.
Bolniku je treba posebej poudariti, da je treba suspenzijo NovoMix 30 tik pred uporabo resuspendirati.
The resuspended liquid must appear uniformly white and cloudy.
Resuspendirana teko ina mora biti enakomerno bela in motna.
The patient should be advised to discard the needle after each injection.
Bolniku je treba naro iti, naj iglo po vsakem injiciranju zavrže.
1 August 2000 Date of last renewal:
1. avgust 2000 Datum zadnjega podaljšanja dovoljenja za promet:
1 August 2005
1. avgust 2005
NovoMix 50 Penfill 100 U/ ml, suspension for injection in a cartridge.
NovoMix 50 Penfill 100 e. / ml suspenzija za injiciranje v injekcijskem vložku
Soluble insulin aspart*/ protamine-crystallised insulin aspart*…… ..100 U/ ml in the ratio of 50/ 50
Topni insulin aspart * / s protaminom kristalizirani insulin aspart *......... 100 e. / ml v razmerju 50/ 50
NovoMix 50 is a white suspension.
Zdravilo NovoMix 50 je bela suspenzija.
When necessary, NovoMix 50 can be given soon after start of a meal.
Hiter za etek delovanja in zgoden vrh delovanja insulina aspart omogo ata uporabo zdravila NovoMix 50 tik pred obrokom. e je potrebno, je mogo e zdravilo NovoMix 50 dati kmalu po za etku obroka.
Dosage of NovoMix 50 is individual and determined on the basis of the physician’ s advice in accordance with the patient’ s needs.
Odmerjanje zdravila NovoMix 50 je individualno in dolo eno na podlagi zdravnikovega nasveta v skladu z bolnikovimi potrebami.
The individual insulin requirement is usually between 0.5 and 1.0 Units/ kg/ day in adult patients and this may be fully or partially supplied with NovoMix 50.
Individualna potreba po insulinu je pri odraslih bolnikih ponavadi od 0, 5 do 1, 0 enot/ kg/ dan in jo lahko v celoti ali delno pokrije zdravilo NovoMix 50.
The daily insulin requirement may be higher in patients with insulin resistance (e. g. due to obesity), and lower in patients with residual endogenous insulin production.
Dnevna potreba po insulinu je lahko ve ja pri bolnikih z odpornostjo proti insulinu (npr. zaradi debelosti) in manjša pri bolnikih z rezidualnim endogenim nastajanjem insulina.
In patients with type 2 diabetes, NovoMix 50 can be given in monotherapy or in combination with metformin, when the blood glucose is inadequately controlled with metformin alone.
Pri bolnikih z diabetesom tipa 2 lahko zdravilo NovoMix 50 uporabite v monoterapiji ali v kombinaciji z metforminom, e glukoza v krvi s samim metforminom ni zadostno urejena.
Transfer to NovoMix 50 from other insulin preparations may require adjustment of dose and timing of administration.
Pri prehodu z drugih insulinov na zdravilo NovoMix 50 utegne biti potrebna prilagoditev odmerka in asa uporabe.
As with all insulins, close glucose monitoring is recommended during transition and the initial weeks thereafter (see section 4.4).
Tako kot pri vseh insulinih je med prehodom in v prvih tednih po prehodu priporo ljivo natan no kontrolirati glukozo (glejte poglavje 4. 4).
Adjustment of dosage may also be necessary if patients change their diet.
Prilagoditev odmerka utegne biti potrebna tudi, e bolniki spremenijo svojo prehrano.
Physical activity may reduce the patients’ insulin requirements.
Telesna dejavnost lahko zmanjša bolnikovo potrebo po insulinu.
In patients with diabetes mellitus optimised metabolic control effectively delays the onset and slows the progression of diabetic late complications.
im boljša urejenost presnove pri bolnikih z diabetesom mellitusom u inkovito odloži nastanek in upo asni napredovanje poznih diabeti nih zapletov.
Optimised metabolic control, including glucose monitoring, is therefore recommended.
Zato je priporo ljiva im boljša urejenost